Eejung Kim

This study shows that KRASG12C inhibitors alter the surface proteome of lung cancer cells, revealing FOLR1 as a new target when combined with an antibody drug conjugate.

This study uses deep mutational scanning to analyze KRAS variants, identifying gain- and loss-of-function mechanisms and their impact on oncogenic activity.

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

This study identifies how mutant KRAS reprograms the noncoding transcriptome, upregulating repetitive noncoding RNAs and inducing IFN-stimulated genes through epigenetic and RNA-based mechanisms.